MithraGen Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

MithraGen General Information


Developer of immunotherapies for T and B cells for the treatment and prevention of cancers and infectious diseases. The company develops immunotherapies incorporating Class I and II restricted epitopes for the treatment of cancers and infectious diseases that currently have no satisfactory therapy.

Contact Information

Formerly Known As
Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Primary Office
  • 8030 El Rio
  • Houston, TX 77054
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MithraGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 01-Jan-2008 00.000 Completed Generating Revenue
3. Early Stage VC (Series B) 12-Mar-2004 00.00 00.000 00.000 Completed Startup
2. Early Stage VC (Series A) $1.89M $1.89M 00.00 Completed
1. Accelerator/Incubator Completed Startup
To view MithraGen’s complete valuation and funding history, request access »

MithraGen Cap Table

Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 0,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Series A 000,000 00.000000 00.00 00 00 00 00 00.000
To view MithraGen’s complete cap table history, request access »

MithraGen Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BCM Ventures Venture Capital Minority 000 0000 000000 0
Emerging Technology Partners (Venture Capital) Corporate Venture Capital Minority 000 0000 000000 0
Wake Forest Baptist Corporation 000 0000 000000 0
To view MithraGen’s complete investors history, request access »